机译:与征准患者的新辅助化学疗法的可耐受性,安全性和结果,用于患者≥70岁,局部晚期直肠癌
Department of Gastroenterology and Hepatology St Antonius Hospital Nieuwegein;
Department of Internal Medicine/Oncology St Antonius Hospital Nieuwegein;
Department of Internal Medicine/Oncology Diakonessenhuis Utrecht;
Department of Internal Medicine/Oncology Meander Medical Center Amersfoort;
Department of Radiotherapy University Medical Center Utrecht;
Department of Surgery St Antonius Hospital Nieuwegein;
Department of Gastroenterology and Hepatology St Antonius Hospital Nieuwegein;
Department of Gastroenterology and Hepatology Radboud University Medical Center Nijmegen;
Department of Gastroenterology and Hepatology St Antonius Hospital Nieuwegein;
Department of Internal Medicine/Oncology St Antonius Hospital Nieuwegein;
Elderly patients; LARC; nCRT; Preoperative chemoradiotherapy; Survival;
机译:与征准患者的新辅助化学疗法的可耐受性,安全性和结果,用于患者≥70岁,局部晚期直肠癌
机译:含有每周晚期氨基替康的局部晚期直肠癌患者骨髓剂量和急性血液学毒性与Capecitabine的化学疗法和Neoadjuvant联合治疗
机译:血红蛋白水平和XRCC1多态性,为患有局部晚期直肠癌候选者的患者进行新辅助化学疗法,用同时的Capecitabine和铂盐
机译:DWI数据的放射线学分析,以鉴定新辅助放化疗后符合局部切除资格的直肠癌患者
机译:强烈的Neoadjuvant治疗局部晚期癌症射线=加强Neoadjuvant治疗局部晚期直肠癌
机译:局部晚期直肠癌的新辅助化疗联合卡培他滨和根治性手术的长期肿瘤学结局:在单个机构中的10年经验
机译:在局部晚期直肠癌患者6周内Neoadjuvant ChemorAderapy的休息期间休息期间额外的4周Capecitabine:长期肿瘤成果